TABLE 1.
Study | Groups included in the study (number of cases) | Area(s) of the brain | Method | References |
---|---|---|---|---|
Masliah et al. (2004) | HIV+ with HIVE (n = 9) vs. HIV+ no HIVE (n = 8) | Frontal Cortex | Microarray | Masliah et al. (2004) |
Gelman et al. (2004) | HIV+ with HAD (n = 5) or MCMD (n = 2) or NPI-O (n = 2) vs. HIV-/Ctl (n = 5) | Frontal cortical grey matter and adjacent gyral white matter | Microarray | Gelman et al. (2004) |
Shapshak et al. (2004) | HIV+ (n = 5 incl. HIVE (n = 3) and/or HAD (n = 3)) vs. HIV-/Ctl (n = 4) | Frontal cortex | Microarray | Shapshak et al. (2004) |
Everall et al. (2005) | HIV+ HIVE/METH (n = 4) vs. HIV+ HIVE, no METH (n = 4) vs. HIV+ no HIVE, no METH (n = 5) | Frontal cortex | Microarray | Everall et al. (2005) |
Borjabad et al. (2011) | HIV+ HAND (n = 8) vs. HIV+ cART, HAND (n = 7) vs. HIV−/Ctl (n = 6) | Deep white matter within anterior frontal lobe | Microarray | Borjabad et al. (2011) |
Gelman et al. (2012) | HIV+ with NCI and HIVE (n = 5) vs. HIV+ with NCI, no HIVE (n = 7) vs. HIV+/CN, no HIVE (n = 6) vs. HIV−/Ctl (n = 6) | Frontal cortex, neostriatum, and white matter from deep frontal lobe | Microarray | Gelman et al. (2012) |
Zhou et al. (2012) | HIV+ with HAD (n = 10) vs. HIV+ no HAD (n = 8) | Frontal Cortex | Microarray | Zhou et al. (2012) |
Levine et al. (2013) | HIV+ with HAD and HIVE (n = 4) vs. HIV+ with HAD, no HIVE (n = 7) vs. HIV+/CN, no HIVE (n = 4) vs. HIV−/Ctl (n = 6 (microarray), n = 8 (WGCNA)) vs. AD+ HIV− (n = 20) | Frontal cortex, neo-striatum, and white matter from deep frontal lobe (see Gelman et al. (2012)) | Microarray and WGCNA | Levine et al. (2013) |
Canchi et al. (2020) | HIV+ with HAD (n = 3) vs. HIV+ with MND (n = 10) vs. HIV+ with ANI (n = 10) vs. HIV+/CN (n = 10) | Frontal Cortex | RNA-seq | Canchi et al. (2020) |
Total n in trans-scriptomic studies | HIV+ with or without NCI or HIVE (n = 143) vs. HIV−/Ctl (n = 29) |